CPHRF (Cipher Pharmaceuticals) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)

What is Cipher Pharmaceuticals LT-Debt-to-Total-Asset?

Cipher Pharmaceuticals CPHRF 96 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates CPHRF with a GF Score™ of 96/100 and a GF Value™ of $12.30 (Fairly Valued). The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Cipher Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

Cipher Pharmaceuticals's long-term debt to total assets ratio declined from Mar. 2025 (0.25) to Mar. 2026 (0.00). It may suggest that Cipher Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

Cipher Pharmaceuticals (OTCPK:CPHRF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Cipher Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Cipher Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Cipher Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cipher Pharmaceuticals LT-Debt-to-Total-Asset Chart

Cipher Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.00

0.25

0.03

Cipher Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.25	0.17	0.09	0.03	0.00

96GF Score

Cipher Pharmaceuticals Inc CPHRF

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cipher Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Cipher Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	5.216	/	156.502
	=	0.03

Cipher Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0.165	/	153.279
	=	0.00

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

Cipher Pharmaceuticals (CPHRF) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Cipher Pharmaceuticals and its competitors.

Is Cipher Pharmaceuticals' LT-Debt-to-Total-Asset too high?

Cipher Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.00. Overall, Cipher Pharmaceuticals has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Cipher Pharmaceuticals' LT-Debt-to-Total-Asset compare to ZTS and UTHR?

Cipher Pharmaceuticals' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Cipher Pharmaceuticals and its competitors. Cipher Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cipher Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Cipher Pharmaceuticals (CPHRF) is currently considered Fairly Valued. The stock's GF Value™ is $12.30, compared to a current price of $11.77 — trading 4.3% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Cipher Pharmaceuticals' overall GF Score™ is 96/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Cipher Pharmaceuticals (CPHRF), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cipher Pharmaceuticals (CPHRF) Overvalued in 2026?

Based on GuruFocus' analysis, Cipher Pharmaceuticals stock appears to be undervalued. The current stock price of $11.77 is trading 4.3% below its estimated GF Value™ of $12.30. GuruFocus considers Cipher Pharmaceuticals to be Fairly Valued.

Key valuation signals for CPHRF:

LT-Debt-to-Total-Asset: 0.00
GF Value™: $12.30 vs. price of $11.77 (4.3% below fair value)
GF Score™: 96/100 with 5 warning signs

No single metric tells the full story. See the CPHRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cipher Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies XCNQ:CL TSX:TSND TSX:WEED NEOE:VRNO TSX:XLY TSX:ACB TSX:OGI TSX:CRDL TSX:LOVE TSXV:RX XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges PHE:Germany CPH:Canada

Address 5750 Explorer Drive, Suite 404, Mississauga, ON, CAN, L4W 0A9

Website https://www.cipherpharma.com

Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing, and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products, among others. The company's geographical operational areas include Canada and the United States.

96GF Score

Get the complete analysis for CPHRF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.77

Price

$12.30

GF Value

View CPHRF Analysis

See LT-Debt-to-Total-Asset data for all stocks →